Repligen (RGEN) Updates FY18 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.71-0.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.71. The company issued revenue guidance of $191-194 million, compared to the consensus revenue estimate of $187.95 million.

Shares of NASDAQ RGEN opened at $58.19 on Thursday. Repligen has a one year low of $29.56 and a one year high of $58.99. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of 84.33, a PEG ratio of 4.39 and a beta of 0.69.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. Repligen had a return on equity of 5.05% and a net margin of 13.49%. The firm had revenue of $49.53 million for the quarter, compared to the consensus estimate of $46.69 million. During the same quarter in the previous year, the company posted $0.15 earnings per share. The business’s quarterly revenue was up 35.4% compared to the same quarter last year. As a group, equities research analysts forecast that Repligen will post 0.71 EPS for the current fiscal year.

Several research firms have recently issued reports on RGEN. Stephens upped their price target on Repligen from $50.00 to $55.00 and gave the stock an average rating in a research note on Tuesday, July 10th. BidaskClub upgraded Repligen from a buy rating to a strong-buy rating in a research note on Friday, August 24th. Zacks Investment Research downgraded Repligen from a hold rating to a sell rating in a research note on Tuesday, August 7th. Citigroup boosted their price objective on Repligen from $45.00 to $56.00 and gave the stock a buy rating in a research report on Friday, July 20th. Finally, Janney Montgomery Scott reissued a buy rating on shares of Repligen in a research report on Thursday, October 4th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. Repligen currently has an average rating of Buy and an average price target of $53.83.

In related news, major shareholder Roy T. Eddleman sold 4,770 shares of the business’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $49.05, for a total transaction of $233,968.50. Following the completion of the transaction, the insider now owns 413,985 shares of the company’s stock, valued at approximately $20,305,964.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of the company’s stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $51.44, for a total value of $121,707.04. Following the completion of the transaction, the director now directly owns 4,988 shares of the company’s stock, valued at approximately $256,582.72. The disclosure for this sale can be found here. Insiders have sold a total of 88,884 shares of company stock valued at $4,693,683 in the last three months. 1.40% of the stock is owned by insiders.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Inflation

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.

Leave a Reply